Pharmafile Logo
Pharmafocus logo
Advanced Search

Strensiq

Showing 5 posts of 5 posts found.

NICE agrees approval deal for ultra-rare juvenile bone disease

July 5, 2017
Research and Development, Sales and Marketing Alexion, NICE, Strensiq

NICE has announced that it has decided to approve Alexion Pharma’s Strensiq (asfotase alfa) for the treatment of ultra-rare disease …

News
alexion

Alexion hits out at NICE ruling on Strensiq

February 8, 2017
Research and Development, Sales and Marketing Alexion, NICE, Strensiq

NICE has again drawn the ire of a company over its recommendation of its drug, this time round it’s Alexion …

News

NICE approval for restricted-use hypophosphatasia therapy

September 23, 2016
Medical Communications, Sales and Marketing Alexion Pharmaceuticals, Strensiq, hypophosphatasia

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of Alexion Pharmaceutical’s Strensiq …

News

NICE turns down bone disorder drug for NHS

December 3, 2015
Research and Development Alexion, NICE, Strensiq

NICE has published draft guidance as part of its highly specialised technologies programme, not recommending Alexion Pharma’s Strensiq (asfotase alfa) …

News
Alexion sign

Alexion scores double EU approval

September 1, 2015
Manufacturing and Production, Sales and Marketing Alexion, EC, European Commission, Kanuma, Strensiq, asfotase alfa, sebelipase alfa, ultra rare disease, ultra-rare disease

Two treatments developed by ultra-rare disease specialists Alexion Pharmaceuticals are now approved for use in Europe. The European Commission approved …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026